Giuseppe Vergaro

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5777663/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Biomarkers for the diagnosis and management of heart failure. Heart Failure Reviews, 2022, 27, 625-643.	3.9	135
2	Current and emerging drug targets in heart failure treatment. Heart Failure Reviews, 2022, 27, 1119-1136.	3.9	22
3	A national survey on prevalence of possible echocardiographic red flags of amyloid cardiomyopathy in consecutive patients undergoing routine echocardiography: study design and patients characterization $\hat{a} \in \mathbb{C}$ the first insight from the AC-TIVE Study. European Journal of Preventive Cardiology, 2022, 29, e173-e177.	1.8	21
4	Creatine deficiency and heart failure. Heart Failure Reviews, 2022, 27, 1605-1616.	3.9	13
5	Restrictive spirometry pattern and abnormal cardiopulmonary response to exercise in transthyretin cardiac amyloidosis. European Respiratory Journal, 2022, 59, 2102838.	6.7	6
6	Prognostic Benefit of New Drugs for HFrEF: A Systematic Review and Network Meta-Analysis. Journal of Clinical Medicine, 2022, 11, 348.	2.4	5
7	High-sensitivity troponins for outcome prediction in the general population: a systematic review and meta-analysis. European Journal of Internal Medicine, 2022, 98, 61-68.	2.2	15
8	Multi-chamber speckle tracking imaging and diagnostic value of left atrial strain in cardiac amyloidosis. European Heart Journal Cardiovascular Imaging, 2022, 24, 130-141.	1.2	18
9	In Vivo Murine Models of Cardiotoxicity Due to Anticancer Drugs: Challenges and Opportunities for Clinical Translation. Journal of Cardiovascular Translational Research, 2022, , 1.	2.4	2
10	RNA-targeting and gene editing therapies for transthyretin amyloidosis. Nature Reviews Cardiology, 2022, 19, 655-667.	13.7	64
11	Critical Comparison of Documents FromÂScientific Societies on CardiacÂAmyloidosis. Journal of the American College of Cardiology, 2022, 79, 1288-1303.	2.8	35
12	Targeting precipitants to prevent heart failure hospitalization. Does season matter?. International Journal of Cardiology, 2022, , .	1.7	0
13	The revolution of ATTR amyloidosis in cardiology: certainties, gray zones and perspectives. Minerva Cardiology and Angiology, 2022, 70, 248-257.	0.7	2
14	Cardiac remodelling–ÂPart 2: Clinical, imaging and laboratory findings. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2022, 24, 944-958.	7.1	22
15	Redefining the epidemiology of cardiac amyloidosis. A systematic review and metaâ€∎nalysis of screening studies. European Journal of Heart Failure, 2022, 24, 2342-2351.	7.1	51
16	Management of complications of cardiac amyloidosis: 10 questions and answers. European Journal of Preventive Cardiology, 2021, 28, 1000-1005.	1.8	12
17	Prognostic value of cardiopulmonary exercise testing in cardiac amyloidosis. European Journal of Heart Failure, 2021, 23, 231-239.	7.1	26
18	Arterial thrombo-embolic events in cardiac amyloidosis: a look beyond atrial fibrillation. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2021, 28, 12-18.	3.0	38

#	Article	IF	CITATIONS
19	A simple echocardiographic score to rule out cardiac amyloidosis. European Journal of Clinical Investigation, 2021, 51, e13449.	3.4	24
20	Renin profiling predicts neurohormonal response to sacubitril/valsartan. ESC Heart Failure, 2021, 8, 719-724.	3.1	3
21	Use of biomarkers to diagnose and manage cardiac amyloidosis. European Journal of Heart Failure, 2021, 23, 217-230.	7.1	33
22	Deep-learning-based cardiac amyloidosis classification from early acquired pet images. International Journal of Cardiovascular Imaging, 2021, 37, 2327-2335.	1.5	16
23	Biopsy Evidence of Sequential Transthyretin and Immunoglobulin Light-Chain Cardiac Amyloidosis in the Same Patient. JACC: Case Reports, 2021, 3, 450-454.	0.6	2
24	Re-appraisal of the obesity paradox in heart failure: a meta-analysis of individual data. Clinical Research in Cardiology, 2021, 110, 1280-1291.	3.3	20
25	Norepinephrine, plasma renin activity and cardiovascular mortality in systolic heart failure. Heart, 2021, 107, 989-995.	2.9	2
26	Quality of life assessment in amyloid transthyretin (ATTR) amyloidosis. European Journal of Clinical Investigation, 2021, 51, e13598.	3.4	16
27	Prognostic value of reverse remodelling criteria in heart failure with reduced or midâ€range ejection fraction. ESC Heart Failure, 2021, 8, 3014-3025.	3.1	11
28	Sacubitril–valsartan treatment is associated with decrease in central apneas in patients with heart failure with reduced ejection fraction. International Journal of Cardiology, 2021, 330, 112-119.	1.7	14
29	Indications of beta-adrenoceptor blockers in Takotsubo syndrome and theoretical reasons to prefer agents with vasodilating activity. International Journal of Cardiology, 2021, 333, 45-50.	1.7	11
30	Molecular Autopsy of Sudden Cardiac Death in the Genomics Era. Diagnostics, 2021, 11, 1378.	2.6	16
31	Evaluation of pathophysiological relationships between renin-angiotensin and ACE-ACE2 systems in cardiovascular disorders: from theory to routine clinical practice in patients with heart failure. Critical Reviews in Clinical Laboratory Sciences, 2021, 58, 530-545.	6.1	9
32	The place of vericiguat in the landscape of treatment for heart failure with reduced ejection fraction. Heart Failure Reviews, 2021, , 1.	3.9	9
33	Discharge FGF23 level predicts one year outcome in patients admitted with acute heart failure. International Journal of Cardiology, 2021, 336, 98-104.	1.7	6
34	Patients with cardiac amyloidosis have a greater neurohormonal activation than those with non-amyloidotic heart failure. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2021, 28, 252-258.	3.0	9
35	Amyloid Deposits and Fibrosis on Left Ventricular Endomyocardial Biopsy Correlate With Extracellular Volume in Cardiac Amyloidosis. Journal of the American Heart Association, 2021, 10, e020358.	3.7	34
36	Cardiac biomarkers retain prognostic significance in patients with heart failure and chronic obstructive pulmonary disease. Journal of Cardiovascular Medicine, 2021, Publish Ahead of Print, 28-36.	1.5	1

#	Article	IF	CITATIONS
37	Keys to early diagnosis of cardiac amyloidosis: red flags from clinical, laboratory and imaging findings. European Journal of Preventive Cardiology, 2020, 27, 1806-1815.	1.8	60
38	How a large registry can explain pathophysiology: The case of anemia in the heart failure syndromes. International Journal of Cardiology, 2020, 298, 72-73.	1.7	0
39	Scoring frailty in patients hospitalized for heart failure: Impact on prognosis (and decision making,) Tj ETQq1 1 0	.784314 r 1.7	gBT /Overloci
40	Circulating levels and prognostic value of soluble ST2 in heart failure are less influenced by age than Nâ€ŧerminal proâ€Bâ€ŧype natriuretic peptide and highâ€sensitivity troponin T. European Journal of Heart Failure, 2020, 22, 2078-2088.	7.1	26
41	Multiparametric Echocardiography Scores for the Diagnosis of CardiacÂAmyloidosis. JACC: Cardiovascular Imaging, 2020, 13, 909-920.	5.3	136
42	Biomarkers for growth prediction of abdominal aortic aneurysm: A step forward(?). European Journal of Preventive Cardiology, 2020, 27, 130-131.	1.8	3
43	Targeting Cyclic Guanosine Monophosphate to Treat HeartÂFailure. Journal of the American College of Cardiology, 2020, 76, 1795-1807.	2.8	71
44	Abdominal Fat Biopsy for the Diagnosis of Cardiac Amyloidosis. JACC: Case Reports, 2020, 2, 1182-1185.	0.6	3
45	Integrated Imaging to Investigate Low-Flow Alarms of LeftÂVentricularÂAssist Devices. JACC: Case Reports, 2020, 2, 1457-1460.	0.6	1
46	Deep learning to diagnose cardiac amyloidosis from cardiovascular magnetic resonance. Journal of Cardiovascular Magnetic Resonance, 2020, 22, 84.	3.3	33
47	The heart failure specialists of tomorrow: a network for young cardiovascular scientists and clinicians. ESC Heart Failure, 2020, 7, 873-877.	3.1	2
48	Wild type transthyretin amyloidosis: Don't miss diagnosis!. International Journal of Cardiology, 2020, 312, 96-97.	1.7	3
49	Safety and Tolerability of Neurohormonal Antagonism in Cardiac Amyloidosis. European Journal of Internal Medicine, 2020, 80, 66-72.	2.2	34
50	Upright Cheyne-Stokes Respiration in Patients With HeartÂFailure. Journal of the American College of Cardiology, 2020, 75, 2934-2946.	2.8	31
51	Safety and efficacy of levosimendan in patients with cardiac amyloidosis. European Journal of Internal Medicine, 2020, 80, 114-116.	2.2	3
52	α-1 Antitrypsin as a potential biomarker in chronic heart failure. Journal of Cardiovascular Medicine, 2020, 21, 209-215.	1.5	3
53	Diphosphonate single-photon emission computed tomography in cardiac transthyretin amyloidosis. International Journal of Cardiology, 2020, 307, 187-192.	1.7	9
54	Cardiac sympathetic denervation in wild-type transthyretin amyloidosis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2020, 27, 237-243.	3.0	10

#	Article	IF	CITATIONS
55	The ST2-SCD score and the conundrum of sudden death prediction in heart failure. International Journal of Cardiology, 2019, 294, 50-51.	1.7	1
56	Contribution of the Lung to the Genesis of Cheyneâ€6tokes Respiration in Heart Failure: Plant Gain Beyond Chemoreflex Gain and Circulation Time. Journal of the American Heart Association, 2019, 8, e012419.	3.7	28
57	Clinical and Prognostic Significance of sST2 in HeartÂFailure. Journal of the American College of Cardiology, 2019, 74, 2193-2203.	2.8	110
58	Sympathetic and renin-angiotensin-aldosterone system activation in heart failure with preserved, mid-range and reduced ejection fraction. International Journal of Cardiology, 2019, 296, 91-97.	1.7	60
59	Central and Obstructive Apneas in Heart Failure With Reduced, Mid-Range and Preserved Ejection Fraction. Frontiers in Cardiovascular Medicine, 2019, 6, 125.	2.4	25
60	Noncardiac Versus Cardiac Mortality in Heart Failure With Preserved, Midrange, and Reduced Ejection Fraction. Journal of the American Heart Association, 2019, 8, e013441.	3.7	62
61	Left ventricular ejection fraction and coronary artery disease in the era of precision medicine. European Journal of Preventive Cardiology, 2019, 26, 1271-1272.	1.8	1
62	Revisiting the obesity paradox in heart failure: Per cent body fat as predictor of biomarkers and outcome. European Journal of Preventive Cardiology, 2019, 26, 1751-1759.	1.8	28
63	Admission high-sensitivity troponin T and NT-proBNP for outcome prediction in acute heart failure. International Journal of Cardiology, 2019, 293, 137-142.	1.7	24
64	No Aldosterone Breakthrough With the Neprilysin Inhibitor Sacubitril. Journal of the American College of Cardiology, 2019, 73, 3037-3038.	2.8	5
65	Treatment of cardiac transthyretin amyloidosis: an update. European Heart Journal, 2019, 40, 3699-3706.	2.2	121
66	Longer sleep duration and poor sleep quality as risk factors for hyperlipidaemia. European Journal of Preventive Cardiology, 2019, 26, 1285-1287.	1.8	3
67	Relative hypochromia in acute heart failure to predict outcome and guide treatment: Ready for prime time?. International Journal of Cardiology, 2019, 286, 111-112.	1.7	Ο
68	Cheyne-Stokes respiration related oscillations in cardiopulmonary hemodynamics in patients with heart failure. International Journal of Cardiology, 2019, 289, 76-82.	1.7	21
69	High-sensitivity troponin T, NT-proBNP and glomerular filtration rate: A multimarker strategy for risk stratification in chronic heart failure. International Journal of Cardiology, 2019, 277, 166-172.	1.7	32
70	Accuracy of 99mTc-Hydroxymethylene diphosphonate scintigraphy for diagnosis of transthyretin cardiac amyloidosis. Journal of Nuclear Cardiology, 2019, 26, 497-504.	2.1	64
71	Mineralocorticoid receptor antagonists for heart failure: a realâ€life observational study. ESC Heart Failure, 2018, 5, 267-274.	3.1	13
72	Sex-related differences in chronic heart failure. International Journal of Cardiology, 2018, 255, 145-151.	1.7	41

#	Article	IF	CITATIONS
73	Natriuretic peptides. D'où venons-nous? Que sommes-nous? Où allons-nous?. International Journal of Cardiology, 2018, 254, 256-257.	1.7	2
74	Prognostic Value of High-Sensitivity Troponin T in Chronic Heart Failure. Circulation, 2018, 137, 286-297.	1.6	157
75	A mechanistic look at sacubitril/valsartan action. Unravelling magician's secrets. International Journal of Cardiology, 2018, 258, 203-204.	1.7	Ο
76	High-Sensitivity TroponinsÂand Prognosis in HeartÂFailure. JACC: Heart Failure, 2018, 6, 440-441.	4.1	0
77	N-terminal fraction of pro-B-type natriuretic peptide versus clinical risk scores for prognostic stratification in chronic systolic heart failure. European Journal of Preventive Cardiology, 2018, 25, 889-895.	1.8	12
78	Wet is bad: Residual congestion predicts worse prognosis in acute heart failure. International Journal of Cardiology, 2018, 258, 201-202.	1.7	6
79	Heart, kidney and FGF23: Les liaisons dangereuses. International Journal of Cardiology, 2018, 253, 120-121.	1.7	1
80	sST2 Predicts Outcome in ChronicÂHeartÂFailure Beyond NTâ^'proBNP and High-Sensitivity Troponin T. Journal of the American College of Cardiology, 2018, 72, 2309-2320.	2.8	126
81	Targeting Inflammation With Nanosized Drug Delivery Platforms in Cardiovascular Diseases: Immune Cell Modulation in Atherosclerosis. Frontiers in Bioengineering and Biotechnology, 2018, 6, 177.	4.1	26
82	NT-proBNP prognostic value is maintained in elderly and very elderly patients with chronic systolic heart failure. International Journal of Cardiology, 2018, 271, 324-330.	1.7	27
83	Therapies for cardiac light chain amyloidosis: An update. International Journal of Cardiology, 2018, 271, 152-160.	1.7	31
84	The IL-33/ST2 pathway, inflammation and atherosclerosis: Trigger and target?. International Journal of Cardiology, 2018, 267, 188-192.	1.7	40
85	ls there a "renal paradox―in chronic heart failure?. International Journal of Cardiology, 2018, 267, 139-140.	1.7	3
86	Quality of life and outcome in heart failure with preserved ejection fraction: When sex matters. International Journal of Cardiology, 2018, 267, 141-142.	1.7	6
87	Healthy hearts at hectic pace: From daily life stress to abnormal cardiomyocyte function and arrhythmias. European Journal of Preventive Cardiology, 2018, 25, 1419-1430.	1.8	11
88	Left ventricular ejection fraction for risk stratification in chronic systolic heart failure. International Journal of Cardiology, 2018, 273, 136-140.	1.7	11
89	Heart & kidney failure: Who's afraid of renin angiotensin system blockade?. International Journal of Cardiology, 2018, 266, 195-196.	1.7	0
90	Breathing Not Properly in the oldest old. Is brain natriuretic peptide a poor test for the diagnosis of heart failure in the elderly <i>?</i> . European Journal of Heart Failure, 2017, 19, 549-551.	7.1	1

#	Article	IF	CITATIONS
91	Meta-Analysis of Soluble Suppression ofÂTumorigenicity-2 and Prognosis in Acute Heart Failure. JACC: Heart Failure, 2017, 5, 287-296.	4.1	104
92	Predicting readmissions after hospitalization for heart failure: Medical reasoning vs calculators. International Journal of Cardiology, 2017, 236, 348-349.	1.7	0
93	PET-CT evaluation of amyloid systemic involvement with [18F]-florbetaben in patient with proved cardiac amyloidosis: a case report. Journal of Nuclear Cardiology, 2017, 24, 2025-2029.	2.1	11
94	Effect of Sex on Reverse Remodeling in Chronic Systolic Heart Failure. JACC: Heart Failure, 2017, 5, 735-742.	4.1	30
95	Are big data on myocardial infarction enough for small heart failure patients? Lessons from a national registry. International Journal of Cardiology, 2017, 248, 278-279.	1.7	1
96	How to take arms against central apneas in heart failure. Expert Review of Cardiovascular Therapy, 2017, 15, 743-755.	1.5	4
97	Cardiac light-chain deposition disease relapsing in the transplanted heart. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2017, 24, 135-137.	3.0	4
98	Prognostic Value of Soluble Suppression of Tumorigenicity-2 in Chronic Heart Failure. JACC: Heart Failure, 2017, 5, 280-286.	4.1	127
99	Clinical benefits of natriuretic peptides and galectin-3 are maintained in old dyspnoeic patients. Archives of Gerontology and Geriatrics, 2017, 68, 33-38.	3.0	4
100	Biomarkers of Heart Failure with Preserved and Reduced Ejection Fraction. Handbook of Experimental Pharmacology, 2016, 243, 79-108.	1.8	7
101	The search for efficient diagnostic and prognostic biomarkers of heart failure. Future Cardiology, 2016, 12, 327-337.	1.2	1
102	Inhibition of Galectin-3 Pathway Prevents Isoproterenol-Induced Left Ventricular Dysfunction and Fibrosis in Mice. Hypertension, 2016, 67, 606-612.	2.7	90
103	Targeting Mitochondrial Dysfunction in Chronic Heart Failure: Current Evidence and Potential Approaches. Current Pharmaceutical Design, 2016, 22, 4807-4822.	1.9	16
104	Refractory hyperaldosteronism in heart failure is associated with plasma renin activity and angiotensinogen polymorphism. Journal of Cardiovascular Medicine, 2015, 16, 416-422.	1.5	12
105	Prognostic significance of myocardial extracellular volume fraction in nonischaemic dilated cardiomyopathy. Journal of Cardiovascular Medicine, 2015, 16, 681.	1.5	61
106	Galectin-3 and myocardial fibrosis in nonischemic dilated cardiomyopathy. International Journal of Cardiology, 2015, 184, 96-100.	1.7	60
107	Measurement of myocardial amyloid deposition in systemic amyloidosis: insights from cardiovascular magnetic resonance imaging. Journal of Internal Medicine, 2015, 277, 605-614.	6.0	44
108	Self-Inserted Needles in the Heart. American Journal of Cardiology, 2015, 116, 1315-1317.	1.6	6

#	ARTICLE	IF	CITATIONS
109	Prognostic markers of acute decompensated heart failure: The emerging roles of cardiac biomarkers and prognostic scores. Archives of Cardiovascular Diseases, 2015, 108, 64-74.	1.6	32
110	Markers of fibrosis, inflammation, and remodeling pathways in heart failure. Clinica Chimica Acta, 2015, 443, 29-38.	1.1	70
111	Biomarkers of activation of renin-angiotensin-aldosterone system in heart failure: how useful, how feasible?. Clinica Chimica Acta, 2015, 443, 85-93.	1.1	22
112	Correction of procedural arterial pseudoaneurysms: established and novel procedures. Expert Review of Cardiovascular Therapy, 2014, 12, 843-850.	1.5	3
113	CHADS2 and CHA2DS2-VASc scores to predict morbidity and mortality in heart failure patients candidates to cardiac resynchronization therapy. Europace, 2014, 16, 71-80.	1.7	64
114	Percutaneous Treatment of latrogenic Pseudoaneurysms by Cyanoacrylate-Based Wall-Gluing. CardioVascular and Interventional Radiology, 2013, 36, 669-675.	2.0	22
115	Prognostic value of plasma renin activity in heart failure patients with chronic kidney disease. International Journal of Cardiology, 2013, 167, 711-715.	1.7	27
116	PLASMA RENIN ACTIVITY AND ANGIOTENSINOGEN M235T POLYMORPHISM ARE DETERMINANTS OF ALDOSTERONE ESCAPE IN PATIENTS WITH SYSTOLIC HEART FAILURE. Journal of the American College of Cardiology, 2011, 57, E260.	2.8	0
117	Prognostic Value of Plasma Renin Activity in Heart Failure. American Journal of Cardiology, 2011, 108, 246-251.	1.6	61
118	Markers of Arrhythmogenic Risk in Hypertensive Subjects. Current Pharmaceutical Design, 2011, 17, 3062-3073.	1.9	8
119	Concordant Versus Discordant Left Bundle Branch Block in Heart Failure Patients: Novel Clinical Value of an Old Electrocardiographic Diagnosis. Journal of Cardiac Failure, 2010, 16, 320-326.	1.7	15
120	Cardiac angiotensin receptor expression in hypothyroidism: back to fetal gene programme?. Journal of Physiology, 2008, 586, 7-8.	2.9	5
121	Clinical relevance of non-cardiac determinants of natriuretic peptide levels. Clinical Chemistry and Laboratory Medicine, 2008, 46, 1515-23.	2.3	24